Take part in a research study of an investigational medicine at no cost.
For more information contact Premier Psychiatric Research Institute at (402) 476-6060 (Option 4) and www.PremierPsych.com.
Date: September 13, 2013
Are you currently not depressed or manic?
Do you feel that your memory or attention are impaired?
If yes, you may be eligible for a study with investigational medicineFor more information, please contact Katie at the Mount Sinai Mood and Anxiety Disorders Research Program: 212-241-3089.
Date: April 18, 2013
If you have schizophrenia, schizoaffective disorder, bipolar disorder, or a gastrointestinal disorder (including trouble with reflux and/or gastric emptying) and experience symptoms of tardive dyskinesia, you’re invited to see if you may qualify for a clinical research study to determine if an investigational drug may help you manage your involuntarymovements.
Each individual must be 18 to 85 years of age, and will be evaluated to determine eligibility. All participants will receive study-related medical exams and lab tests at no charge. Compensation for time and travel may be available.
Date: April 10, 2013
Locations: Lincoln and Omaha, Nebraska
Do you have?
You must be:
Please contact Premier Psych at(402) 817-2218 or TMS@PremierPsych.com for more information.
Date: February 28, 2013
What is this study about?
Who is eligible?
What do you have to do?
How long does it take?
What are the risks?
What do you receive?
Please contact Amanda Bender, MS 310-478-3711 ext. 49234 for more information
Date: January 24, 2013
The UCLA Mood Disorders Research Program is conducting a study in people with bipolar disorder who are currently depressed. The study seeks to understand changes in the brain that occur with successful treatment. The study will involve a psychiatric history interview, mood questionnaires, free medication for depression, free psychiatrist visits for 10 weeks and MRI scans before and after treatment.
You may be compensated up to $100 per MRI scan and up to $175 for clinical follow-up.
Currently we are looking for individuals who:
To learn more, please call 310-794-6663
Principal Investigator: Lori Altshuler, M.D. Protocol
Date: May 2, 2012
The Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder study (PGBD) is a research study of patients with bipolar disorder and the role of genes in their response to medications. The study focuses on two of the most commonly used mood stabilizing medications, lithium and valproate (Depakote(r)). The goal is to identify the genes that influence whether a patient will have a good response to these medications.
Clinical Treatment with Lithium
Lithium is the best known and most widely used medication for bipolar disorder. If you have bipolar disorder and are willing and able to be treated with lithium, you may be eligible to participate in the study. If you participate in this clinical trial, you will receive a state of the art diagnostic evaluation and expert treatment with lithium. You may also receive compensation. Most people with bipolar disorder can be successfully treated with lithium, which has been shown to be the most effective medication for maintaining stability. The goal is to treat you with lithium alone, which may reduce the number of side effects you may experience.
Subjects can enter the study on multiple psychotropic medications. However, the goal is to attain lithium monotherapy within a maximum of 16 weeks. During this time, other mood stabilizers, antidepressants, and antipsychotics will be tapered.
For Eligibility Requirements, What to Expect and Study Locations, please visit our website http://www.lithium.ucsd.edu/participation/ or contact Anna Demodena (below).
Date: Oct. 6, 2011
This study is testing the effectiveness of riluzole versus placebo for decreasing anxiety in children with pediatric bipolar disorder (BP). Children and youth with bipolar disorder display episodic elevated mood and associated symptoms of decreased need for sleep, increased goal-directed behavior, and increased self-esteem/grandiosity.
Children ages 9 to 17 with BP may be eligible to participate in this 12- to 15-week inpatient or outpatient study. This study has four phases. During Phase I, participants are gradually withdrawn from all current psychotropic medications. Phase II is a one-week medication-free period. During Phase III, which lasts two weeks, participants are randomly assigned to also receive either riluzole or placebo (a “sugar pill”). Phase IV lasts for 6 weeks. During this time, participants continue riluzole or placebo.
At the end of the study, those who received placebo have the opportunity to receive riluzole.
All procedures and medications associated with the research are provided at no cost to participants, and assistance with transportation and lodging expenses is available. Schooling will be provided while on the inpatient unit or in day treatment.
To find out if you qualify or for more information, please call (301) 496-8381 or email us at firstname.lastname@example.org.
National Institute of Mental Health
National Institutes of Health
Department of Health & Human Services
[The principal researcher is Ellen Leibenluft, M.D., Chief, Unit on Affective Disorders, NIMH Pediatrics and Developmental Neuropsychiatry Branch]
Location: By telephone, web or email.
If you answered "yes", we would love to hear from you! We are UBC researchers who have developed a questionnaire to help measure internalized stigma in first-degree relatives of people with a severe mental illness.
What is the purpose of the research?
Stigma affects individuals with a mental illness and their family members. The purpose of this study is to validate a questionnaire that we have recently developed to measure internalized stigma in first-degree family members (parents, brothers, sisters, and children) of people with schizophrenia, bipolar disorder, or schizoaffective disorder. The questionnaire will be used to gather information about how family members of people with mental illness experience stigma, which can also be helpful in evaluating the well being of family members. Later on, the questionnaire will also be used in the development and evaluation of strategies to reduce individuals’ internalized stigma.
Who can participate?
Parents, siblings, and children of people with schizophrenia, schizoaffective disorder, or bipolar disorder. We are looking for both men and women to participate in this study.
What is involved in participating?
If you participate in this study you will be asked to complete questionnaires at two time points that are one month apart. The questionnaires include the new stigma questionnaire as well as 7 other questionnaires (that ask about things like self-esteem and mood).
You do not have to travel to participate in this study; you can participate entirely from home by telephone and mail/email.
Each time point should take approximately 30 – 45 minutes of your time to complete.
How do I participate?
If you are interested in participating, please contact the Research Coordinator (Emily) at: 604-875-2000 x4732 or by email at email@example.com
Posted: August 10, 2010
Researchers at the National Human Genome Research Institute of the National Institutes of Health are seeking parents who have been diagnosed with bipolar disorder to participate in an online survey. The survey will take about 45 minutes to complete. In the survey, we ask questions about participants’ thoughts about their bipolar disorder and how they deal with bipolar disorder. We also ask about participants’ thoughts about the chance that their children might get a mood disorder someday, and how they feel about that chance. The survey is completely anonymous.
To participate, you must:
Your child cannot have been diagnosed with a mood disorder or other serious psychiatric disorder. Your child cannot have been adopted. You must be (or must have been) involved in taking care of your child. Your child must be younger than 30 years of age.
Taking the survey could make you uncomfortable. If you become uncomfortable, you can stop taking the survey. There are no benefits to participating.
If you would like to participate, please go to http://www.surveymonkey.com/s/parents_with_bipolar to take the survey.
If you have questions about the study, please contact the study co-investigator, Holly Peay, at firstname.lastname@example.org or 301- 496-3979.
Posted Jan 7, 2010
You may be eligible to participate in the study if you meet these conditions:
The total amount of time it takes to complete the study is approximately 14-16 hours. Transportation can be provided if needed. All participants will be compensated for their time.
For more details, call our research coordinator, Jennifer Jones, at 410-402-6823
Posted: April 15, 2009
Is your child or teen being treated for bipolar I disorder and still experiencing symptoms?
Your child or teen may qualify to participate in a clinical research study in your area evaluating an investigational medication as a potential add-on treatment for bipolar I disorder in children and teens ages 10-17. Children and teens enrolled in this study may continue on their current prescribed medications. Each participant will receive comprehensive, study-related evaluations and investigational study medication at no cost. Compensation for time and travel may also be provided to those who qualify. Please call The Ohio State University, Department of Psychiatry Clinical Research Office at 614-293-7109 or e-mail email@example.com to learn more.
Posted: February 17, 2009